Please login to the form below
small cell lung cancer
This page shows the latest small cell lung cancer news and features for those working in and with pharma, biotech and healthcare.
BMS shares positive phase 3 results for Opdivo/Yervoy combination in colorectal cancer
More than 1.9 million cases of colorectal cancer were diagnosed globally in 2020. ... Opdivo plus Yervoy-based combinations already hold approvals for a range of indications, including certain cases of melanoma, non-small cell lung cancer (NSCLC),
Latest news
-
Roche shares positive late-stage results for inavolisib combination in advanced breast cancer
multiple cancer types, including certain types of breast, lung, liver and bladder cancer. ... in a subset of non-small cell lung cancer patients.
-
AstraZeneca gains rights to Usynova’s KRAS inhibitor in deal worth almost $420m
AstraZeneca (AZ) has entered into an exclusive licence agreement with Chinese biotech Usynova for global rights to preclinical small molecule drug candidate UA022, with the deal worth almost $420m. ... UA022 targets the KRAS G12D mutation, the most
-
Merck receives FDA approval for Keytruda combination in gastric cancer
Last month, the therapy was approved in the US as part of a combination treatment for patients with earlier stages of lung cancer. ... The approval specifically applies to patients with resectable non-small cell lung cancer and means that Keytruda can
-
Bristol Myers Squibb's lung cancer drug Augtyro receives FDA approval
cell lung cancer (NSCLC). ... Lung cancer is the leading cause of cancer deaths in the US, with NSCLC representing up to 85% of all lung cancer diagnoses.
-
Novartis gains global rights to Legend’s CAR-T cell therapies in deal worth over $1bn
Legend is taking into early-stage clinical development for extensive stage small cell lung cancer and large cell neuroendocrine carcinoma. ... The preclinical evidence shows that an autologous CAR-T could be a differentiated treatment option for patients
More from news
Approximately 32 fully matching, plus 740 partially matching documents found.
Latest Intelligence
-
The promise of precision medicine
Conditions classified as rare diseases affect a relatively small percentage of people in the world. ... The most promising results seen to date show that genetic information has helped boost the survival rates of those suffering from advanced
-
Successful product commercialisation: what can we learn from the rare disease setting?
With an increasing number of drug trials in crowded markets such as oncology (for example, in non-small cell lung cancer and multiple myeloma), understanding patient needs is not only critical ... For novel therapies (including medicines aimed at rare
-
Unlocking the potential of precision medicine in oncology
Targeted therapies. Furthermore, by following a similar trajectory in the treatment of non-small cell lung cancer (NSCLC), where we are studying specific alterations in the epidermal growth factor receptor (EGFR), ... We are following a similar approach
-
BiTE* platform and the evolution toward off-the-shelf immuno-oncology approaches
Amgen brought the first approved BiTE molecule targeting CD19 to patients and we continue to pioneer the bispecific space by exploring this technology across solid tumors, such as small-cell lung ... the other is designed to engage with any
-
Guiding star of science leads AstraZeneca to breakthrough in child tumour therapy
targets of small cell lung cancer and melanoma in adults, while its licensing became embroiled in a royalties dispute. ... The NF1 gene provides instructions to make neurofibromin which acts as a tumour suppressant but if it mutates, tumour cell growth
More from intelligence
Approximately 0 fully matching, plus 28 partially matching documents found.
Latest appointments
-
Merck’s R&D chief Roger Perlmutter heads for the exit as Dean Li takes the helm
newly-diagnosed non-small cell lung cancer (NSCLC) patients.
-
Merck appoints ex-Pfizer exec as global head of oncology
In this role, she will be responsible for defining the pharmaceutical company's integrated global oncology strategies and delivering therapeutic launches, including the commercial launch of Avelumab, a non-small cell ... lung cancer therapy, which is
-
BIND Therapeutics appoints Andrew Hirsch as permanent CEO
Its lead compound, BIND-014, is currently in phase II clinical trials for KRAS-mutant and squamous histology non-small cell lung cancer.
-
Charles Morris appointed chief development officer at ImmunoGen
Dr Morris, who joins from Allos Therapeutics, will oversee all aspects of product development for the US cancer-focused biotech. ... Its pipeline includes the investigational compounds IMGN901 - in phase II testing for the treatment of small-cell lung
-
Axelar appoints Carl Harald Janson as CEO
Takes control as company prepares to take novel cancer drug to proof-of-concept. ... The biotech is currently running a randomised phase II clinical trial with AXL1717 in non-small cell lung cancer (NSCLC) patients, while a first-in-man phase I/II
More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest from PMHub
-
Oncology eBook: Reducing the care gap in cancer prevention, diagnosis, and treatment
Despite significant innovation in the oncology landscape, there is a growing care gap preventing patients accessing and benefiting from innovations in cancer treatment. ... A case study on determining endpoints in non-small-cell lung cancer.
-
The heavy toll of COVID-19 on cancer patients
During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. ... The therapy works predominantly on non-small cell lung cancer. The NHS has also rolled out four chemo-buses which allowed patients to take part in therapy
-
Delphi Technique Virtual Co-creation: A Customer Story
The client’s main objectives were to:. Determine the current barriers to biomarker testing and biomarker-based treatment for non-small cell lung cancer (NSCLC), including differences in regional access and
-
Therapy Watch expands oncology and IBD portfolios
Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer ... PCa), Renal Cell Carcinoma (RCC) and
-
Therapy Watch expands its oncology portfolio
This month Therapy Watch Oncology will be expanding its portfolio with the addition of Squamous Cell Carcinoma of the Head and Neck (SCCHN). ... Therapy Watch SCCHN is part of a wider portfolio which covers Chronic Lymphocytic Leukaemia (CLL),
More from PMHub
Approximately 0 fully matching, plus 7 partially matching documents found.
Subscribe to our email news alerts
- OPEN Health and Nested Knowledge announce strategic research collaboration to leverage AI technologies for evidence synthesis
- FDA approves two cell-based gene therapies for sickle cell disease
- Pfizer’s Elrexfio granted EC approval for relapsed and refractory multiple myeloma
- New economic data reveals risk of disincentivising UK life sciences growth
- WHO countries hold seventh INB meeting to prevent global pandemics
- The start of a beautiful friendship
No results were found
PMHub
nzyme
The nzyme group focuses on the three fundamentals that enable full patient access - Education, Access & Activation. Our specialist...
Latest intelligence
- Virtual care – negotiating barriers to adoption offers glimpses of an exciting future
- Digital tools and innovative healthcare promise to address pressing healthcare issues if they can satisfy concerns over access, security and affordability...
- Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
- ...
- New Playbook Alert: Virtual Patient Engagement
- ...
